We recently published a list of 16 Best Mid Cap Growth Stocks To Buy Now. In this article, we are going to take a look at ...

Review highlights the growing evidence that aging is linked to reduced expression of long genes, offering insights into ...

RBC Capital analyst Luca Issi maintained a Hold rating on Moderna (MRNA – Research Report) today and set a price target of $75.00. The ...

Genomics is on the brink of revolutionizing healthcare with breakthroughs that could redefine treatment and diagnosis. As ...

Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today that on September 17, 2024, the Company received ...

Modified nucleotides like m5C in saRNA enhance vaccine efficacy, stability, and reduce inflammation, offering a promising ...

Analysts have recently evaluated Editas Medicine and provided 12-month price targets. The average target is $11.75, ...

Today engineers are putting their own spin on DNA computing, to both record data and serve as biological computers, yet until ...

Moderna Inc. (NASDAQ: MRNA) made headlines during the pandemic for its messenger ribonucleic acid (mRNA) technology used in ...

A recent study has identified new biochemistry for RNA functions at low temperatures. Ribonucleic acid (RNA) is a vital ...